MiNK Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period
MiNK Therapeutics, Inc. (INKT) reported Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period of 80.93 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod · last filed 2026-08-13
- MiNK Therapeutics, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for the quarter ending 2026-06-30 was 13.76K shares, a 31.56% decline year-over-year.
- MiNK Therapeutics, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for the quarter ending 2026-03-31 was 67.17K shares.
- MiNK Therapeutics, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for the quarter ending 2025-12-31 was 8.29K shares.
- MiNK Therapeutics, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for the quarter ending 2025-09-30 was 41.14K shares, a 48.89% decline year-over-year.
- MiNK Therapeutics, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for fiscal 2025 was 69.53K shares, a 118.18% increase from fiscal 2024.
- MiNK Therapeutics, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for fiscal 2024 was 31.87K shares, a 97.96% decline from fiscal 2023.
- MiNK Therapeutics, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for fiscal 2023 was 1.56M shares, a 623.07% increase from fiscal 2022.
- MiNK Therapeutics, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for fiscal 2022 was 216.21K shares, a 68.92% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 3 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | 13.76K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | 80.93K shares 10-Q · filed 2026-08-13 | 89.22K shares derived: sum of 3 quarters · filed 2026-08-13 | 130.36K shares derived: sum of 4 quarters · filed 2026-08-13 | |
| 2026-03-31 | 67.17K shares 10-Q · filed 2026-05-15 | 75.46K shares derived: sum of 2 quarters · filed 2026-05-15 | 116.60K shares derived: sum of 3 quarters · filed 2026-05-15 | 136.70K shares derived: sum of 4 quarters · filed 2026-05-15 | |
| 2025-12-31 | 8.29K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | 49.43K shares derived: sum of 2 quarters · filed 2026-03-31 | 69.53K shares derived: sum of 3 quarters · filed 2026-03-31 | 69.53K shares 10-K · filed 2026-03-31 | |
| 2025-09-30 | 41.14K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | 61.24K shares derived: sum of 2 quarters · filed 2025-11-14 | 61.24K shares 10-Q · filed 2025-11-14 | -123.20K shares derived: sum of 4 quarters · filed 2026-05-15 | |
| 2025-06-30 | 20.10K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | 20.10K shares 10-Q · filed 2025-08-14 | -164.34K shares derived: sum of 3 quarters · filed 2026-05-15 | -83.84K shares derived: sum of 4 quarters · filed 2026-05-15 | |
| 2025-03-31 | 0.00 shares 10-Q · filed 2026-05-15 | 9.03K shares 10-Q · filed 2025-05-15 | -184.44K shares derived: sum of 2 quarters · filed 2026-05-15 | -103.95K shares derived: sum of 3 quarters · filed 2026-05-15 | -37.61K shares derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | -184.44K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | -103.95K shares derived: sum of 2 quarters · filed 2025-03-18 | -37.61K shares derived: sum of 3 quarters · filed 2025-03-18 | 31.87K shares 10-K · filed 2025-03-18 | |
| 2024-09-30 | 80.50K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | 146.84K shares derived: sum of 2 quarters · filed 2024-11-14 | 216.31K shares 10-Q · filed 2024-11-14 | 1.01M shares derived: sum of 4 quarters · filed 2024-11-14 | |
| 2024-06-30 | 66.34K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | 135.81K shares 10-Q · filed 2024-08-13 | 933.86K shares derived: sum of 3 quarters · filed 2024-08-13 | 988.23K shares derived: sum of 4 quarters · filed 2024-08-13 | |
| 2024-03-31 | 69.48K shares 10-Q · filed 2024-05-14 | 867.52K shares derived: sum of 2 quarters · filed 2024-05-14 | 921.89K shares derived: sum of 3 quarters · filed 2024-05-14 | 965.99K shares derived: sum of 4 quarters · filed 2024-05-14 | |
| 2023-12-31 | 798.04K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | 852.41K shares derived: sum of 2 quarters · filed 2024-03-21 | 896.51K shares derived: sum of 3 quarters · filed 2024-03-21 | 1.56M shares 10-K · filed 2024-03-21 | |
| 2023-09-30 | 54.37K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | 98.47K shares derived: sum of 2 quarters · filed 2023-11-14 | 765.28K shares 10-Q · filed 2023-11-14 | 795.69K shares derived: sum of 4 quarters · filed 2023-11-14 | |
| 2023-06-30 | 44.10K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | 710.91K shares 10-Q · filed 2023-08-10 | 741.32K shares derived: sum of 3 quarters · filed 2023-08-10 | 801.92K shares derived: sum of 4 quarters · filed 2023-08-10 | |
| 2023-03-31 | 666.81K shares 10-Q · filed 2023-05-11 | 697.22K shares derived: sum of 2 quarters · filed 2023-05-11 | 757.82K shares derived: sum of 3 quarters · filed 2023-05-11 | 757.82K shares derived: sum of 4 quarters · filed 2023-05-11 | |
| 2022-12-31 | 30.41K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-24 | 91.01K shares derived: sum of 2 quarters · filed 2023-03-24 | 91.01K shares derived: sum of 3 quarters · filed 2023-03-24 | 216.21K shares 10-K · filed 2023-03-24 | |
| 2022-09-30 | 60.59K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | 60.59K shares derived: sum of 2 quarters · filed 2022-11-03 | 185.79K shares 10-Q · filed 2022-11-03 | 185.79K shares derived: sum of 4 quarters · filed 2022-11-03 | |
| 2022-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | 125.20K shares 10-Q · filed 2022-08-15 | 125.20K shares derived: sum of 3 quarters · filed 2022-08-15 | ||
| 2022-03-31 | 125.20K shares 10-Q · filed 2022-05-13 | 125.20K shares derived: sum of 2 quarters · filed 2022-05-13 | |||
| 2021-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-18 | 695.75K shares 10-K · filed 2022-03-18 | |||
| 2021-09-30 | 695.75K shares 10-Q · filed 2021-11-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |